Bank Julius Baer & Co. Ltd, Zurich Cassava Sciences Inc Transaction History

Bank Julius Baer & Co. Ltd, Zurich

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	SELL	$32.6 - $53.05 $13,040 - $21,220	-400 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$36.77 - $90.91 $14,708 - $36,364	400 New	400 $17,000
Q3 2021 Nov 12, 2021	SELL	$41.79 - $135.3 $459,773 - $1.49 Million	-11,002 Closed	0 $0
Q2 2021 Jul 23, 2021	SELL	$32.15 - $89.72 $16,010 - $44,680	-498 Reduced 4.33%	11,002 $940,000
Q1 2021 May 10, 2021	BUY	$7.09 - $87.95 $81,535 - $1.01 Million	11,500 New	11,500 $517,000

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $94.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.